Cat. #154120
Anti MRCKa [2A3]
Cat. #: 154120
Unit size: 100 ug
Availability: 10-12 weeks
Target: MRCKÄÂ?
Class: Monoclonal
Application: IP ; WB
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Thomas Leung
Institute: A*STAR Accelerate Technologies Pte Ltd
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti MRCKa [2A3]
- Research fields: Cell biology
- Class: Monoclonal
- Conjugation: Unconjugated
- Application: IP ; WB
- Description: The MRCKLRAP35a-MYO18A complex plays a major role in the assembly of the lamellar actomyosin retrograde flow bundles important for persistent membrane protrusion. The complex may also represent a mode of transmitting signals from leading edge to cell center, as part of the coordination mechanism important for efficient and persistent directional migration.
Target Details
- Target: MRCKÄÂ?
- Target background: The MRCKLRAP35a-MYO18A complex plays a major role in the assembly of the lamellar actomyosin retrograde flow bundles important for persistent membrane protrusion. The complex may also represent a mode of transmitting signals from leading edge to cell center, as part of the coordination mechanism important for efficient and persistent directional migration.
Applications
- Application: IP ; WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- Tan et al. 2008. Cell. 135(1):123-36. PMID: 18854160.
- A tripartite complex containing MRCK modulates lamellar actomyosin retrograde flow.
